High-anxious Individuals Show Increased Chronic Stress Burden, Decreased Protective Immunity, and Increased Cancer Progression in a Mouse Model of Squamous Cell Carcinoma
Overview
Authors
Affiliations
In spite of widespread anecdotal and scientific evidence much remains to be understood about the long-suspected connection between psychological factors and susceptibility to cancer. The skin is the most common site of cancer, accounting for nearly half of all cancers in the US, with approximately 2-3 million cases of non-melanoma cancers occurring each year worldwide. We hypothesized that a high-anxious, stress-prone behavioral phenotype would result in a higher chronic stress burden, lower protective-immunity, and increased progression of the immuno-responsive skin cancer, squamous cell carcinoma. SKH1 mice were phenotyped as high- or low-anxious at baseline, and subsequently exposed to ultraviolet-B light (1 minimal erythemal dose (MED), 3 times/week, 10-weeks). The significant strengths of this cancer model are that it uses a normal, immunocompetent, outbred strain, without surgery/injection of exogenous tumor cells/cell lines, and produces lesions that resemble human tumors. Tumors were counted weekly (primary outcome), and tissues collected during early and late phases of tumor development. Chemokine/cytokine gene-expression was quantified by PCR, tumor-infiltrating helper (Th), cytolytic (CTL), and regulatory (Treg) T cells by immunohistochemistry, lymph node T and B cells by flow cytometry, adrenal and plasma corticosterone and tissue vascular-endothelial-growth-factor (VEGF) by ELISA. High-anxious mice showed a higher tumor burden during all phases of tumor development. They also showed: higher corticosterone levels (indicating greater chronic stress burden), increased CCL22 expression and Treg infiltration (increased tumor-recruited immuno-suppression), lower CTACK/CCL27, IL-12, and IFN-γ gene-expression and lower numbers of tumor infiltrating Th and CTLs (suppressed protective immunity), and higher VEGF concentrations (increased tumor angiogenesis/invasion/metastasis). These results suggest that the deleterious effects of high trait anxiety could be: exacerbated by life-stressors, accentuated by the stress of cancer diagnosis/treatment, and mediate increased tumor progression and/or metastasis. Therefore, it may be beneficial to investigate the use of chemotherapy-compatible anxiolytic treatments immediately following cancer diagnosis, and during cancer treatment/survivorship.
Esdaille A, Kuete N, Anyaeche V, Kalemoglu E, Kucuk O Cancers (Basel). 2024; 16(17).
PMID: 39272881 PMC: 11394332. DOI: 10.3390/cancers16173023.
Zhang J, Deng Y, Liu J, Gan L, Jiang Y Cancer Biol Ther. 2024; 25(1):2366451.
PMID: 38857055 PMC: 11168221. DOI: 10.1080/15384047.2024.2366451.
Hassan M, Tawakol A, Wang Y, Alvi R, Awadalla M, Jones-OConnor M PLoS One. 2023; 18(8):e0279235.
PMID: 37540647 PMC: 10403142. DOI: 10.1371/journal.pone.0279235.
Working with Convex Responses: Antifragility from Finance to Oncology.
Taleb N, West J Entropy (Basel). 2023; 25(2).
PMID: 36832709 PMC: 9955868. DOI: 10.3390/e25020343.
Geng Q, Li L, Shen Z, Zheng Y, Wang L, Xue R Br J Cancer. 2023; 128(7):1223-1235.
PMID: 36646807 PMC: 10050078. DOI: 10.1038/s41416-022-02132-7.